Dalfampridine Associated Serious Adverse Events: An Analysis of Data from the Food and Drug Administration’s Adverse Event Reporting System

SUMMARY. Dalfampridine, a voltage-dependent potassium channel blocker, has been shown to improve walking in patients with multiple sclerosis. However, it could cause several side effects such as weakness, multiple sclerosis relapse, dizziness, painful urination, and balance problems. The present study aimed to describe the adverse events associated with dalfampridine. A descriptive analysis was conducted to analyze all reported adverse events associated with dalfampridine using the US FDA Adverse Event Reporting System (FAERS). Most of the reports were submitted by consumers (73.45%) and only about 25% of the reports were submitted by healthcare professionals. The most reported adverse events were classified as adverse events linked to treatment such as (ineffective drug (12.44%), multiple sclerosis relapse (5.48%), and condition aggravated (5.30%)) and adverse events linked to events such as (gait disturbance (15.62%), fall (9.59%), balance disorder (6.62%), fatigue (6.46%), dizziness (5.60%). It is essential to increase awareness of health care professionals about dalfampridine’s side effects to ensure patient safety.